
apr pm et
summari compani develop da vinci surgic system use advanc robot
computer visual technolog minimally-invas surgeri
price-to-earnings oper ep
risk assess base highli competit
environ robot surgeri new competitor
enter market isrg requir complianc
 foreign regul potenti legal
liabil injuri may result use
ep estim base cfra oper earn histor
earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr stock trade
expect sale rise
billion follow rise see
growth driven increas gener
urolog procedur growth
intern market partial off-set
continu soft core gynecolog
surpass gynecolog largest
specialti look procedur volum
increas encourag
stabil revenu per procedur
instrument accessori revenu per
procedur similar
compar
aid increas sale
stapl vessel seal product
base compar year-end
look gross margin improv
basi point see
oper margin improv basi point
see ep util
tax rate
complet stock split octob
think share -- current trade
ep estim peer
near high end five-year
rang -- near fair valu see
improv procedur volum aid
robust intern growth see
receiv fda approv robot senhanc
impact sale elong sale cycl
view howev decemb
submit da vinci sp platform
urolog believ da vinci sp
signific advantag could drive growth
enabl high dexter access
vision confin surgic space plan
first market da vinci sp urolog
surgeri head neck surgeri colorect
risk recommend target price
includ lower procedur volum
project price pressur competit
target price assum
multipl ep estim
peer domin market share
high-end five-year rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
intuit surgic design da vinci surgic system product incorpor advanc
robot computer visual technolog improv abil surgeon perform
complex minimally-invas procedur year-end compani instal base
da vinci surgic system year-end respect
year-end respect surgeon use compani
technolog success complet surgic procedur
outsid variou type includ urolog gynecolog cardiothorac gener surgeri
surgic procedur
da vinci surgic system consist surgeon consol patient-sid cart high perform
vision system proprietari wrist instrument place computer-enhanc technolog
surgeon patient think da vinci let surgeon perform better surgeri manner never
experienc system translat surgeon natur hand movement instrument control
consol correspond micro-mov instrument posit insid patient
small punctur incis port give surgeon intuit control rang motion fine tissu
manipul capabl visual characterist open surgeri simultan
allow use small port minimally-invas surgeri
intuit strategi target establish intuit surgeri standard complex surgic
procedur mani procedur time compani hope broaden number
procedur perform use da vinci surgic system educ surgeon hospit
benefit approach
decemb held ownership exclus field-of-us licens
foreign patent foreign patent applic manufactur
market use class ii medic devic da vinci system govern extens
regul administ fda think act signific barrier entri competitor
may surgeon use compani technolog success perform think first
computer-enhanc closed-chest heart surgeri earli surgeon use technolog
success complet compani think world first beat heart bypass procedur
use small port juli fda clearanc obtain system assist control
intuit surgic endoscop instrument laparoscop procedur cholecystectomi gall
bladder remov nissen fundopl correct esophag reflux
march fda clear da vinci minim invas non-cardiac chest surgeri may
fda approv obtain laparoscop radic prostatectomi fda approv da vinci use
mitral valv repair surgeri novemb atrial septal defect closur januari juli
receiv clearanc coronari anastomosi adjunct mediastinotomi cardiac
revascul procedur april receiv fda clearanc gynecolog laparoscop
second quarter launch fourth surgic arm upgrad option da vinci
arm allow complex procedur januari introduc da vinci
share core technolog da vinci standard sever enhanc featur
first quarter launch da vinci tenaculum use hysterectomi
myomectomi gynecolog procedur earli launch high definit hd vision system
provid enhanc visual tissu plane critic anatomi
april introduc da vinci si system includ enhanc hd resolut greater
compat oper room suit technolog upgrad architectur option dual
consol second surgeon provid da vinci enabl assist earli launch da vinci
skill simul practic tool give user opportun practic facil
surgeon consol control first quarter launch firefli fluoresc imag product
allow surgeon identifi vasculatur three dimens beneath tissu surfac visual
critic anatomi meanwhil februari receiv ce mark da vinci single-sit
instrument kit allow da vinci si system work singl incis rather multipl
incis decemb receiv fda approv market single-sit instrument
think compani continu alloc oper cash flow toward growth surgic
robot busi rather consid acquisit outsid area
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu view mani product
categori histor recession-resist
expect continu grow growth
procedur rate area view
non-elect cardiac rhythm
manag intervent cardiolog
orthoped steadili improv
see continu recoveri
medic devic tax requir
healthcar reform law went effect
januari temporarili suspend
januari
congress pass stopgap measur includ
suspend medic devic tax anoth
two year tax
slate becom effect januari
decemb congress pass tax cut
job act includ repeal
individu mandat compon
afford act requir
peopl health insur pay fine
effect januari believ repeal
individu mandat result fewer
insur peopl neg impact
equip sub-industri fewer insur
patient would like lead fewer procedur
anticip hospit
largest buyer medic equip would also
advers impact could
pressur sub-industri
expect revenu rise constant
currenc mid- upper-singl digit pace
aid new product expans emerg
market case acquisit
still expect extend replac cycl
 hospit area price
pressur lower demand certain product
categori affect sale growth also think
 hospit becom cautiou
regard capit budget amid shift
base index
five-year market price perform apr
procedur inpati
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
 composit index year
date april health
declin composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
rang ep vs estim sale
rose procedur rose growth gener surgeri world-wide
urolog procedur ship da vinci system compar year
ago increas instal base year ago
encourag procedur growth isrg strongest sinc see
continu solid growth instal base expand /jeffrey loo cfa
et capit iq keep hold opinion share
intuit surgic keep target
peer revis ep estim
warrant market leadership set ep ep
vs ahead estim sale rose procedur
rose driven gener surgeri urolog world-wide
growth due matur market
et cfra lower sector
marketweight overweight project defens
sector record below-market ep growth addit expect
investor gravit toward cyclic sector result project
increas defens infrastructur spend new republican
administr total return potenti group neutral cfra
equiti analyst posit invest recommend market-averag
percentag compon compani final cfra proprietari technic
indic consum stapl select sector spdr fund xlv ow
et cfra keep hold opinion share intuit surgic
inc keep target peer
next ep estim ep vs
ahead estim rais ep estim
sale rose da vinci procedur grew ship da vinci
system vs year ago instrument revenu per procedur per
procedur last year increas sale stapl vessel
seal product see soft oversea sale china brazil
instrument placement oper leas sale recogn later
analyst research note compani news
et cfra maintain hold opinion share intuit
surgic inc maintain target
above-p next ep estim ep
substanti beat expect due strong sale
million compar consensu estim million sale rose
year-over-year primarili due system revenu growth driven
system ship vs weaker us dollar
million revenu deferr world-wide procedur grew
growth us gener surgeri world-wide urolog procedur although
growth remain formid concern potenti impact
futur develop competit altern da vinci machin
execut risk launch new product inventori increas
seemingli excess level think may tie anticip product
launch rais ep estim ep
estim increas /kevin huang
et cfra keep hold opinion share intuit surgic
inc rais target price
peer ep estim near high
end five-year rang set ep ep
vs ahead estim sale grew da vinci
procedur rose driven gener surgeri procedur
surpass gynecolog largest specialti ship da vinci
system compar system year ago although anticip solid
increas procedur anticip growth moder
inc keep target peer
ep estim near high-end rang
ep vs ahead view rais
ep estim world-wide da vinci procedur rose
driven gener surgeri world-wide urolog procedur drive sale
growth forecast howev note
competitor nr receiv fda approv senhanc
robot system last week think competit could elong sell cycl
rais target price
split-adjust peer ep estim
split adjust also rais ep estim
look sale rise increas
procedur partial off-set slight declin revenu per procedur
also expect system revenu grow higher system placement
partial off-set lower sell price lower leas buy-out
ep estim report result octob /jeffrey
et cfra keep hold opinion share intuit surgic
inc rais target
peer forward ep estim slightli
mid-point rang ep vs
ahead estim ship da vinci system year
ago last quarter world-wide procedur grew robust hernia
repair colon procedur matur categori urolog
gynecolog stabil see continu solid procedur growth
instal base rose rais ep estim
et cfra keep hold opinion share intuit surgic
rais target peer
revis ep estim near mid-point
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
